<DOC>
	<DOCNO>NCT01786395</DOCNO>
	<brief_summary>This study multicenter trial perform Japan , consist comparative study period continuous administration period . Effect 0.15 % UF-021 eye drop improvement central retinal sensitivity HFA verify 52 week comparative study period placebo-controlled , double-masked study patient retinitis pigmentosa . The safety eye drop also examine 52 week continuous administration period , patient complete comparative study period .</brief_summary>
	<brief_title>Phase III Efficacy Safety Clinical Study UF-021 Treatment Retinitis Pigmentosa</brief_title>
	<detailed_description />
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Isopropyl unoprostone</mesh_term>
	<criteria>1 . Age : 20 year , 70 year less ( obtain inform consent ) 2 . Medical examination classification : Outpatients 3 . Observation , examination , surveillance accordance study protocol judge feasible . 4 . ETDRS visual acuity test judge feasible distance 4 meter . 5 . HFA ( 102 ) test judge feasible investigator . 6 . Goldmann perimetry show concentric central visual field loss ( include ring scotoma ) central 30 degree less . 7 . The difference mean retinal sensitivity four central point must less 3 dB two reliable measurement HFA ( 102 ) ( SITAStandard ) conduct within 31 day value worse 30 dB . ( When criterion meet two test , 3rd measurement implement within 31 day 2nd test . The difference 3rd reliable measurement value 1st 2nd measurement must less 3 dB , value worse 30 dB ; recent data regard data acquire instillation . ) 1 . Judged difficulty investigator visit hospital return home safely study period . 2 . Planning undergo ophthalmic operation eye efficacy evaluation study period . 3 . Current treatment glaucoma ocular hypertension . 4 . Prior ophthalmectomy evisceration eye 5 . Intraocular surgery within past five month . 6 . History allergy drug ( instillation narcotic , fluorescein , etc . ) use clinical study , drug similar investigational product 7 . Complications diabetic retinopathy . 8 . Complications external eye inflammation , infectious disease , severe dry eye . 9 . Use isopropyl unoprostone past present . 10 . Use follow drug within 31 day obtain informed consent . Calcium antagonist , Dark adaptation improvement drug ( helenien ) 11 . Participation UF021 phase â…¡ trial ( include subject assign placebo group ) . 12 . Participation clinical study within past 6 month ( However , subject administer investigational product accept ) 13 . Pregnancy possibility become pregnant . Currently breastfeed . Childbearing patient wish become pregnant clinical study period use appropriate contraceptive measure . 14 . Conerod dystrophy cone function primarily impair 15 . History optic nerve disease eye efficacy evaluation 16 . Complications moderate severe ( grade 3 Emery classification ) central cataract , anterior subcapsular cataract , posterior subcapsular cataract , posterior capsule opacification may exert major influence visual acuity eye efficacy evaluation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>UF-021</keyword>
	<keyword>unoprostone</keyword>
	<keyword>rp</keyword>
</DOC>